Covid Reinfection “Very Uncommon”, Not A Matter Of Issue: Top Medical Body

    0
    0
    covid-reinfection-“very-uncommon”,-not-a-matter-of-issue:-top-medical-body

    Covid Reinfection 'Very Rare', Not A Matter Of Concern: Top Medical Body

    ICMR DG Balram Bhargava stated reinfection was “extremely, very uncommon” with COVID-19 (File)

    New Delhi:

    Coronavirus reinfection is possible although it is a “very unusual” occurrence, ICMR DG Balram Bhargava said on Tuesday and stressed that it is not a matter of major concern.

    The remarks come amidst suspected cases of COVID-19 reinfection being reported from abroad and from Indian states like Telangana, Karnataka, Gujarat, Punjab and Maharashtra.

    Responding to a question on the concern, Mr Bhargava informed a press conference that reinfection was “extremely, really unusual” with COVID-19, but it can occur as had actually been seen in a case in Hong Kong.

    ” We have seen that somebody gets measles and he is supposed to be secured all his life since he generates specific antibodies, however then we have actually seen reinfection taking place in measles.

    ” Likewise, we can have reinfection with COVID-19 as has been explained by the case in Hong Kong and it is not a matter of major concern,” Mr Bhargava stated.

    In an earlier interview, he had actually said that there was a requirement to find out how long the immunity lasts versus the infection.

    On coronavirus vaccine advancement, the ICMR director general said 3 vaccines are at clinical trial stages in the nation and two indigenously ones established by Cadila and Bharat Biotech have completed phase-I trial.

    The outcomes are being analysed and they have finished recruitment for the second stage, he stated.

    Serum Institute of India has actually completed stage II-B3 trials of the Oxford COVID-19 vaccine prospect. There was a pause of 7 days. They will begin the phase-III trial with 1,500 patients at 14 places in India after clearances, Mr Bhargava stated.

    The Drugs Controller General of India (DCGI) had actually directed Serum Institute of India to suspend any brand-new recruitment in the phase-II and III clinical trial of the Oxford COVID-19 vaccine candidate till more orders in the backdrop of pharma giant AstraZeneca pausing the clinical trials in other countries.

    Discussing the vaccine developed in Russia, the ICMR DG stated their very first research study of 76 patients has actually been released in the journal Lancet, which is “showing great effectiveness and immune-antibody generation”. He said Russia has not yet finished Phase-III trial.

    Dialogues are going on in between the High-Level Committee on Vaccines and the Russian diplomats about the systems for performing Phase-III trial in India, he said.

    British-Swedish biopharmaceutical huge AstraZeneca and the University of Oxford had on Saturday said that clinical trials for their coronavirus vaccine have actually resumed in the United Kingdom after Medicines and Health care items Regulatory Agency (MHRA) validated that the trials were safe.

    The human trials resumed days after a pause had been announced in the trials after an unfavorable reaction in among the individuals.

    Dealing with an inquiry on the nationwide sero-survey, Mr Bhargava stated the study, which was performed in April-May and is being duplicated after three months, has been finished in 68 out of 70 districts. After analysis of the results by this month end, the two studies can be compared, he said.

    The senior authorities added that the sero-survey also draws out infection death rate, which was discovered to be in between 0.5-0.6 in the last nationwide sero-survey, which was much below than in numerous other countries.

    Source

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here